Novel biomarkers distinguishing pancreatic head Cancer from distal cholangiocarcinoma based on proteomic analysis

BMC Cancer

Table 4 Diagnostic performances of 5 candidate proteins and biomarker panels

Target	Positive in PHC	Positive in DCC	SN	SP	LR (+) (95% CI)	LR (−)(95% CI)	P-value
Single marker for PHC diagnosis
KRT17	55/72	21/74	76.4%	71.6%	2.69 (2.50–2.90)	0.330 (0.299–0.364)	0.0001
ANXA10	59/72	36/74	81.9%	51.3%	1.68 (1.63–1.72)	0.352 (0.303–0.408)	0.0001
TMEM109	48/72	27/74	66.7%	63.5%	1.82 (1.72–1.94)	0.525 (0.490–0.563)	0.0003
Single marker for DCC diagnosis
PTMS	20/72	45/74	60.8%	72.2%	2.19 (2.04–2.35)	0.543 (0.520–0.566)	0.0001
ATP1B1	30/72	45/74	60.8%	58.3%	1.45 (1.39–1.54)	0.672 (0.635–0.711)	0.031
Panel for PHC diagnosis
KRT17+/ANXA10+/PTMS-	34/72	6/74	47.2%	91.9%	5.82 (4.18–8.11)	0.574 (0.559–0.590)	0.0001
Panel for DCC diagnosis
KRT17−/ANXA10−/PTMS+	2/72	17/74	23.0%	97.2%	8.27 (3.46–19.7)	0.792 (0.786–0.798)	0.0003

PHC Pancreatic head cancer, DCC Distal cholangiocarcinoma, SN Sensitivity, SP Specificity, LR (+) Positive likelihood ratio, LR (−) Negative likelihood ratio, CI Confidence interval

ISSN: 1471-2407